Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
A 58% majority of registered voters express unease about voting for Trump, but slightly more say the same about Joe Biden and Bernie Sanders, while Elizabeth Warren fares only...Politicsread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
A temporary airspace closure forced flights coming into Dubai from Australia, Singapore and India to be diverted to nearby airports.Airlinesread more
Schiff had previously shied away from calling for impeachment, but his comments on CNN's "State of the Union" indicate his stance has shifted.Politicsread more
As the home to major companies such as Garmin, Sprint, H&R Block and Russell Stover Chocolates, plenty of business travelers find themselves in Kansas City for work. Here's...Travelread more
The United States aims to avoid war with Iran and the additional troops ordered to be deployed in the Gulf region are for "deterrence and defense," U.S. Secretary of State...Politicsread more
Now, after a set of proposals counter to the industry's interests leading into the midterm elections, Read's support sounds as if it may be waning. One tenet in particular — a plan announced last week to tie prices of certain drugs paid for by Medicare to an international average — has Read and other pharma leaders speaking out.
"I don't believe that the proposed rule in reference pricing to price-controlled markets as a way of setting prices in the U.S. is good for innovation, patients or our industrial base," Read told CNBC in a telephone interview Tuesday.
The administration announced its Blueprint to Lower Drug Prices in May, and was generally met with support from the drug industry.
In particular, pharmaceutical companies like Pfizer lauded the administration's plan to target drug rebates. Those are the discounts drugmakers give to middlemen such as pharmacy benefit managers, often in exchange for more favorable insurance coverage for their medicines. Drug companies argue the rebating system helps drive the price of medicines artificially higher.
When Pfizer decided to defer its planned price hikes earlier this year, it said the current prices would remain until the end of the year, or until the blueprint goes into effect. Under Read's definition, the latter doesn't appear likely before year-end.
"We don't think the blueprint could be implemented other than seeing a radical change in the pricing model by insuring that rebates get to the patient," Read told CNBC. "I feel that they've been less rapid than I'd have liked on this discount issue."
Read said he hopes the administration will revise its plan to tie drug prices covered by Medicare Part B to an international average that's much lower than what the U.S. currently pays. Medicare is the government insurer for the elderly and disabled, and Part B drugs are those administered in the hospital or doctor's office, rather than being dispensed at a pharmacy.
Read did say he is "quite positive about increasing competition in the Part B space," another aspect of the administration's recent proposal.
Industry experts have noted the timing of the Trump administration's most recent moves seem orchestrated around the midterm elections. Drug pricing is a popular campaign issue on both sides of the aisle.
Read, who hands the Pfizer CEO role to Chief Operating Officer Albert Bourla in January, takes a longer-term view.
"I've been in the industry 41 years," he said, "and pricing has always been an issue."